Shui Mu Molecular and DingTalk launch large model for pharmaceutical vertical, lowering the barrier to new drug development!

On December 23, Dingling and Shuimu Molecular launched Chat DD by Dingling—a large model application dedicated to the biopharmaceutical field—and announced a strategic collaboration. This initiative aims to provide life science and biopharmaceutical companies with a professional knowledge engine based on multimodal large models, lower the barriers to new drug development, and advance global health.

Jointly Exploring Deep Applications of AI in Biopharma

At the AI Dingling 1.1 launch event and ecosystem conference, Xing Jie, Chief Operating Officer of Beijing Shuimu Molecular Biotechnology Co., Ltd., was invited to speak alongside Chen Hang, founder and CEO of Dingling. They shared recent progress in multimodal large models for the biopharmaceutical sector and discussed their shared vision for collaboration.

Shuimu Molecular, incubated in June 2023 by Tsinghua University's Institute for Artificial Intelligence (AIR), is committed to building foundational large models and agent platforms for life sciences. Leveraging advanced multimodal AI technologies, the company accelerates innovation across the entire biopharmaceutical and biomanufacturing value chain.

The company has independently developed the foundational model Chat DD FM® and the open-source model OpenBioMed, offering end-to-end support from drug project initiation and target discovery to molecular design and clinical research. Currently, Chat DD is available on Dingling Select, serving dozens of domestic and international life science and pharmaceutical enterprises—including major pharmaceutical companies and small-to-medium innovative firms—by providing ready-to-use AI tools and intelligent solutions that significantly enhance R&D efficiency.

A Decade-Long Relationship Rekindled: Building a New Paradigm for Intelligent R&D

Xing Jie noted that the partnership between Shuimu Molecular and Dingling dates back ten years, when both parties collaborated on a WuXi AppTec project to drive digital transformation in the pharmaceutical industry, integrating mobile solutions for personnel flow, logistics, and information flow. Their renewed collaboration now focuses on deepening R&D empowerment through multi-agent systems and leveraging innovative products like DingTalk Real to bridge the digital and physical worlds, driving transformative change in the industry.

For decades, new drug development has been constrained by the "double ten rule"—an average of 10 years and $1 billion in investment. Today, development cycles have stretched to 15 years, with costs often exceeding $2 billion. Xing pointed out that traditional methods are approaching their limits in terms of efficiency and cost, making AI the key to breakthroughs. In the future, by constructing "virtual agent teams" that simulate different expert roles, autonomous collaboration in biological and clinical research could drastically reduce development timelines and expenses.

According to Shuimu Molecular’s projections, by 2025, nearly 30% of drug development projects will incorporate AI technology, growing at an annual rate of 5%. Within five years, there could be 1.5 novel drugs fully discovered by AI platforms. AI is expected to improve R&D efficiency by 40%-60% and reduce costs by 30%-70%. Xing emphasized, "AI is reshaping the landscape of drug discovery. Through continuous investment and co-creation of use cases, we believe even small, intelligent teams will be able to bring new drugs to market at extremely low cost."

This collaborative innovation between Shuimu Molecular and Dingling marks a new phase in the real-world application of AI within specialized industries. Both parties will continue to deepen their partnership, jointly advancing the pharmaceutical industry toward greater intelligence, efficiency, and affordability, injecting technological momentum into global health.

We dedicated to serving clients with professional DingTalk solutions. If you'd like to learn more about DingTalk platform applications, feel free to contact our online customer service or email at This email address is being protected from spambots. You need JavaScript enabled to view it.. With a skilled development and operations team and extensive market experience, we’re ready to deliver expert DingTalk services and solutions tailored to your needs!